Financial PerformanceSAB reported 4Q23 EPS of ($3.38), versus the estimate of ($0.64) due to several one-time charges, leading to a decrease in the full-year 2024 EPS estimate to ($4.90) from ($1.78).
Financial PerformanceSAB reported 4Q23 EPS of ($3.38), versus the estimate of ($0.64) due to several one-time charges, leading to a decreased full-year 2024 EPS estimate.
RisksRisks associated with the company's progress include commercial, regulatory, clinical, manufacturing, financial, liability, and intellectual challenges.